vs

Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and IRIDEX CORP (IRIX). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $9.5M, roughly 1.5× ECB Bancorp, Inc.). On growth, ECB Bancorp, Inc. posted the faster year-over-year revenue change (33.8% vs -69.7%). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs 11.9%).

ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

ECBK vs IRIX — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.5× larger
IRIX
$14.7M
$9.5M
ECBK
Growing faster (revenue YoY)
ECBK
ECBK
+103.6% gap
ECBK
33.8%
-69.7%
IRIX
Faster 2-yr revenue CAGR
ECBK
ECBK
Annualised
ECBK
23.8%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ECBK
ECBK
IRIX
IRIX
Revenue
$9.5M
$14.7M
Net Profit
$2.6M
Gross Margin
37.2%
Operating Margin
36.7%
Net Margin
27.3%
Revenue YoY
33.8%
-69.7%
Net Profit YoY
79.5%
EPS (diluted)
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ECBK
ECBK
IRIX
IRIX
Q4 25
$9.5M
$14.7M
Q3 25
$8.8M
$12.5M
Q2 25
$8.0M
$13.6M
Q1 25
$6.9M
$11.9M
Q4 24
$7.1M
$12.7M
Q3 24
$6.6M
$11.6M
Q2 24
$6.3M
$12.6M
Q1 24
$6.2M
$11.8M
Net Profit
ECBK
ECBK
IRIX
IRIX
Q4 25
$2.6M
Q3 25
$2.4M
$-1.6M
Q2 25
$1.4M
$-994.0K
Q1 25
$1.3M
$-1.7M
Q4 24
$1.4M
$-834.0K
Q3 24
$1.1M
$-1.9M
Q2 24
$791.0K
$-2.7M
Q1 24
$621.0K
$-3.5M
Gross Margin
ECBK
ECBK
IRIX
IRIX
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
ECBK
ECBK
IRIX
IRIX
Q4 25
36.7%
Q3 25
37.0%
-11.3%
Q2 25
23.9%
-6.9%
Q1 25
24.9%
-1.7%
Q4 24
27.3%
-3.9%
Q3 24
23.3%
-16.1%
Q2 24
16.9%
-20.9%
Q1 24
13.4%
-28.0%
Net Margin
ECBK
ECBK
IRIX
IRIX
Q4 25
27.3%
Q3 25
27.7%
-12.6%
Q2 25
18.0%
-7.3%
Q1 25
18.7%
-14.2%
Q4 24
20.3%
-6.6%
Q3 24
17.2%
-16.7%
Q2 24
12.6%
-21.2%
Q1 24
10.0%
-29.5%
EPS (diluted)
ECBK
ECBK
IRIX
IRIX
Q4 25
$0.32
Q3 25
$0.29
$-0.09
Q2 25
$0.17
$-0.06
Q1 25
$0.16
$-0.10
Q4 24
$0.18
$-0.05
Q3 24
$0.14
$-0.12
Q2 24
$0.09
$-0.16
Q1 24
$0.07
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ECBK
ECBK
IRIX
IRIX
Cash + ST InvestmentsLiquidity on hand
$82.8M
$6.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$171.9M
Total Assets
$1.6B
$29.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ECBK
ECBK
IRIX
IRIX
Q4 25
$82.8M
$6.0M
Q3 25
$201.9M
$5.6M
Q2 25
$191.0M
$6.8M
Q1 25
$143.7M
$7.2M
Q4 24
$309.4M
$2.4M
Q3 24
$114.8M
$3.9M
Q2 24
$108.7M
$4.1M
Q1 24
$109.8M
$5.4M
Total Debt
ECBK
ECBK
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
ECBK
ECBK
IRIX
IRIX
Q4 25
$171.9M
Q3 25
$169.3M
$4.7M
Q2 25
$168.3M
$6.1M
Q1 25
$168.6M
$852.0K
Q4 24
$168.3M
$2.1M
Q3 24
$166.0M
$2.6M
Q2 24
$166.5M
$4.2M
Q1 24
$165.8M
$6.5M
Total Assets
ECBK
ECBK
IRIX
IRIX
Q4 25
$1.6B
$29.2M
Q3 25
$1.6B
$28.4M
Q2 25
$1.5B
$31.6M
Q1 25
$1.5B
$34.2M
Q4 24
$1.4B
$29.1M
Q3 24
$1.4B
$30.2M
Q2 24
$1.3B
$31.2M
Q1 24
$1.3B
$34.1M
Debt / Equity
ECBK
ECBK
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ECBK
ECBK
IRIX
IRIX
Operating Cash FlowLast quarter
$9.2M
Free Cash FlowOCF − Capex
$9.0M
FCF MarginFCF / Revenue
94.7%
Capex IntensityCapex / Revenue
2.2%
Cash ConversionOCF / Net Profit
3.55×
TTM Free Cash FlowTrailing 4 quarters
$14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ECBK
ECBK
IRIX
IRIX
Q4 25
$9.2M
Q3 25
$4.0M
$-1.2M
Q2 25
$1.9M
$-397.0K
Q1 25
$-631.0K
$-1.1M
Q4 24
$6.2M
$-1.2M
Q3 24
$861.0K
$-3.1M
Q2 24
$1.4M
$-1.3M
Q1 24
$-429.0K
$-1.6M
Free Cash Flow
ECBK
ECBK
IRIX
IRIX
Q4 25
$9.0M
Q3 25
$4.0M
$-1.2M
Q2 25
$1.8M
$-410.0K
Q1 25
$-649.0K
$-1.2M
Q4 24
$6.2M
$-1.2M
Q3 24
$-3.1M
Q2 24
$1.3M
Q1 24
$-449.0K
$-1.7M
FCF Margin
ECBK
ECBK
IRIX
IRIX
Q4 25
94.7%
Q3 25
44.9%
-9.4%
Q2 25
23.0%
-3.0%
Q1 25
-9.4%
-9.8%
Q4 24
86.8%
-9.8%
Q3 24
-26.5%
Q2 24
21.4%
Q1 24
-7.2%
-14.0%
Capex Intensity
ECBK
ECBK
IRIX
IRIX
Q4 25
2.2%
Q3 25
0.8%
0.1%
Q2 25
0.6%
0.1%
Q1 25
0.3%
0.1%
Q4 24
0.8%
0.1%
Q3 24
0.0%
0.0%
Q2 24
0.6%
0.0%
Q1 24
0.3%
0.0%
Cash Conversion
ECBK
ECBK
IRIX
IRIX
Q4 25
3.55×
Q3 25
1.65×
Q2 25
1.32×
Q1 25
-0.49×
Q4 24
4.31×
Q3 24
0.76×
Q2 24
1.75×
Q1 24
-0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons